5 Best Gas Utility Stocks For 2014

Wall Street notched another win today as optimism for a strong earnings season continued to grow. The Dow Jones Industrial Average (DJINDICES: ^DJI  ) moved up 76 points, or 0.5%, to close at 15,300, its highest closing mark in three weeks. Alcoa (NYSE: AA  ) got things started off on the right foot, beating adjusted earnings and revenue expectations in its report last night, though shares finished down 0.1% today after gaining 1.4% in the run-up yesterday. A large restructuring charge caused the manufacturer to report a $119 million loss. As the first Dow component to report and the worst-performing this year, Alcoa’s beat seems to have reassured the market. Analysts have also lowered the bar significantly for earnings this quarter, as the consensus for S&P 500 companies’ earnings growth is at just 2.9%, down from 6.1% in April. In the first quarter, those stocks grew profits by 5.4%.

Oddly enough, Alcoa’s strong report did nothing for itself but sent shares of fellow traveler Caterpillar (NYSE: CAT  ) up 2.6%. The two are the worst-performing Dow stocks this year, as they are subject to many of the same market forces, including the vagaries of the business cycle, construction demand, and growth in China. Consequently, Alcoa’s earnings beat is a good reason to bet Caterpillar could also top expectations. Analysts are projecting earnings per share of $1.72 and revenue of $15.04 billion, both sharply down from a year ago, when the heavy equipment manufacturer reports on July 24.

5 Best Gas Utility Stocks For 2014: Ivanhoe Energy Inc (IVAN)

Ivanhoe Energy Inc. (Ivanhoe), incorporated on February 21, 1995, is an independent international heavy oil development and production company. Ivanhoe’s core operations are in Canada, Ecuador, China and Mongolia, with business development opportunities worldwide. Ivanhoe’s wholly owned subsidiary, Sunwing Energy Ltd. (Sunwing) is focused on a natural gas exploration project (the Zitong Block) in Sichuan Province of China. The Sichuan Basin is located in central China approximately 930 miles southwest of Beijing. Its oil and gas operations are located in three geographic areas: Asia, Canada and Ecuador. In December 2012, the Company had closed the Share Purchase and Sale Agreement with MIE Holdings Corporation for all of the interest of its indirect, wholly owned subsidiary, Pan-China Resources Ltd.

Asia

In China, Sunwing operates the 659,840-acre (1,031-square-miles) Zitong gas exploration block in the Sichuan Province, and it holds a 90% Con tractor Interest in a Petroleum Contract with PetroChina Company Limited. Mitsubishi Gas Chemical Company of Japan holds the remaining 10% Contractor Interest. Sunwing produces approximately 1,800 (gross) barrels of light oil per day in Dagang, in China’s Hebei province, in a production sharing agreement with Petrochina in which Sunwing is the operator and maintains a royalty interest in the revenue stream from its first project carried out in the Daqing Oil Field. In November 2002, the Company entered into a 30 year production sharing contract (PSC) with China National Petroleum Corporation (CNPC) for the Zitong block, which covers an area of approximately 248,000 gross acres after contractual relinquishments in the Sichuan basin.

During the year ended December 31, 2006, the Company farmed out 10% of its working interest in the Zitong block to Mitsubishi Gas Chemical Company Inc. of Japan. In Phase I of the contract, Ivanhoe reprocessed 1,649 miles of two dime nsional (2D) seismic data and acquired 705 miles of new 2D s! eismic data. In Phase II of the contract, the Yixin-2 and Zitong-1 gas wells were drilled during the year ended December 31, 2010, and completed during the year ended December 31, 2011. Ivanhoe’s oil production originates in the Kongnan oilfield in Dagang, Hebei Province, China (the Dagang field). In 2011, production in averaged 967 barrels per day net. The Company’s Nyalga Block XVI is in the Khenti and Tov provinces in Mongolia. The block covers an area of approximately 3.1 million gross acres, after a 25% relinquishment in 2010.

Canada

Ivanhoe holds a 100% working interest in the Tamarack Project, subject only to a 20% back-in right held by Talisman Energy. Tamarack is a 6,880 acre lease located approximately 10 miles northeast of Fort McMurray, Alberta, Canada. The Tamarack integrated oil sands project (Tamarack Project) consists of a two-phased 40,000 bbl/d steam-assisted gravity drainage thermal recovery (SAGD) and HTL facility.

Ecuador

The Company’s activities in Latin America are carried out under its wholly owned subsidiary, Ivanhoe Energy Latin America Inc. Ivanhoe Energy Ecuador Inc., a Canadian company is a wholly owned subsidiary of Ivanhoe Energy Latin America Inc. and is responsible for the Company’s activities in Ecuador. In October 2008, Ivanhoe Energy Ecuador Inc. had signed a 30 year contract with the Ecuador state oil companies Petroecuador and Petroproduccion. The contract gives Ivanhoe the right to explore and develop the Pungarayacu heavy oil field in Block 20, an area of 426 square miles, approximately 125 miles southeast of Quito, Ecuador’s capital city. Block 20 is an area of approximately 426-square-miles (1,103.34-square-kilometers) located 125 miles (201.17 kilometers) southeast of Quito. Block 20 contains the 250-square-mile (647.5-square-kilometer) Pungarayacu oil field. In 2010, Ivanhoe drilled its two appraisal wells in the Pungarayacu field. The second, IP-5b, well was drilled, cored and logged to a total depth ! of 1,080 ! feet. The well was perforated in the Hollin oil sands and steam was injected into the reservoir resulting in production of heated heavy oil. In 2011, the heavy crude oil extracted from the IP-5B well was upgraded to local pipeline specifications using Ivanhoe’s HTL upgrading process. In 2011, the Company completed a 190-kilometer 2-D seismic survey over the southern portion of Block 20.

Advisors’ Opinion:

  • [By Stephan Dube]

    Athabasca’s most notable producers:

    Suncor Energy (SU) (Part 1), see article here.Suncor Energy (Part 2), see article here.Athabasca Oil (ATHOF.PK), see article here.Canadian Natural Resources, see article here.Imperial Oil, see article here.Cenovus Energy (CVE), see article here.MEG Energy (MEGEF.PK), see article here.Devon Energy, see article here.Royal Dutch Shell, see article here.Ivanhoe Energy (IVAN), see article here.Nexen (CNOOC) (CEO), see article here.

    An analysis of the current operations of the company will be examined with the objective to provide the most complete information available to potential investors before deciding to seize the opportunity that the 54,132 square miles of the Carbonate Triangle has to offer. Let’s start by introducing Athabasca, a famous and most prolific region in the Canadian oil sands as well as one of the largest reserve in the world.

5 Best Gas Utility Stocks For 2014: National Retail Properties (NNN)

National Retail Properties, Inc. is a publicly owned equity real estate investment trust. The firm acquires, owns, manages, and develops retail properties in the United States. It provides complete turn-key and built-to-suit development services including market analysis, site selection and acquisition, entitlements, permitting, and construction management. The firm also focuses on purchasing and financing net-leased retail properties. It was formerly known as Commercial Net Lease Realty, Inc. National Retail Properties was founded in August 1984 and is based in Orlando, Florida.

Advisors’ Opinion:

  • [By Dan Burrows]

    Here are the three dependable dividend stocks that are up at least 10% year-to-date, as of Feb. 11:

    Dependable Dividend Stocks: National Retail Properties (NNN)

    Dividend Yield: 4.9%
    YTD Gain: 10%

  • [By Charles Sizemore]

    ARCP has a shorter trading history than some of its peers, such as Realty Income (O) and National Retail Properties (NNN), which largely explains why its yield is higher. As a relatively new REIT, ARCP stock is largely unfollowed by investors. But once its merger with Cole Properties (COLE) is completed, ARCP will be the largest trip-net REIT by market cap and total square footage, and it will no longer be flying under Wall Street’s radar.

5 Best Gas Utility Stocks For 2014: Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company’s molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual’s risk for developing disease later in life, determine a patient’s likelihood of responding to a particular drug, assess a patient’s risk of disease progression and disease recurre nce and measure a patient’s exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company’s BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman’s risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company’s total revenue during the fiscal year ended June 30, 2012. Its The Company’s COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person’s risk of developing colorectal cancer or uterine cancer.

The Company’s COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company’s MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company’s OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in opt imizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company’s PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person’s risk of developing pancreatic cancer later in life. The Company’s PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company’s Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company’s TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

C ompanion Diagnostic Services and Other Revenue

! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company’s technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company’s menu of biomarkers. The Company’s companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company’s internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Myriad Genetics (NASDAQ: MYGN) was also up, gaining 12.86 percent to $39.67 after the Centers for Medicare & Medicaid Services updated pricing for the sequencing of the BRCA1 and BRCA2 genes.

  • [By Jake L’Ecuyer]

    Myriad Genetics (NASDAQ: MYGN) was also up, gaining 13.04 percent to $39.74 after the Centers for Medicare & Medicaid Services updated pricing for the sequencing of the BRCA1 and BRCA2 genes.

  • [By Lisa Levin]

    Myriad Genetics (NASDAQ: MYGN) surged 12.89% to $39.68. The volume of Myriad Genetics shares traded 286% higher than normal. The Centers for Medicare & Medicaid Services updated pricing for the sequencing of the BRCA1 and BRCA2 genes.

5 Best Gas Utility Stocks For 2014: Uralkaliy OAO (URALL.PK)

Uralkaliy OAO (Uralkali OJSC) is a Russia-based company, which is engaged in the chemical industry. The Company specializes in the production of potash fertilizers. Its product portfolio comprises pink muriate of potash (PMOP), white muriate of potash (WMOP) and granular (GMOP). The Company is active through representative offices, located in Moscow and Beijing, as well as numerous subsidiaries, located countrywide and in Panama, Belarus, Singapore, Brazil and others. Uralkaliy OAO operates on the potassium and magnesium deposits located in Berezniki, Perm and Saint Petersburg. Its production assets include seven plants and five mines. Uralkaliy OAO sells its products domestically, as well as abroad in over 40 countries, including the United States, China, Brazil, India and South-East Asia, among others. Advisors’ Opinion:

  • [By Tim Gallagher]

    The potash spat continues to get uglier, as Belarus investigators reportedly intend to seize property and assets of Russia’s Uralkali (URALL.PK) following the collapse of the joint Russian-Belarussian potash venture.

  • [By Chris Damas]

    This morning Russian potash giant OJSC Uralkali (URALL.PK) presented first half 2013 financial and operating results and more importantly, much anticipated comments on the strategy of the company and the state of the international potash industry, the latter blind-sided by the leading potash company’s split with marketing partner JSC Belaruskali of Belarus.

5 Best Gas Utility Stocks For 2014: American Capital Agency Corp (AGNC)

American Capital Agency Corp. (AGNC) is a real estate investment trust (REIT). The Company earns income primarily from investing on a leveraged basis in agency mortgage-backed securities. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by government-sponsored entities, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac), or by a United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) (collectively, GSEs). It may also invest in agency debenture securities issued by Freddie Mac, Fannie Mae or the Federal Home Loan Bank (FHLB). The Company is managed by American Capital AGNC Management, LLC, which is an affiliate of American Capital, Ltd.

AGNC funds its investments primarily through short-term borrowings structured as repurchase agreements. The agency mortgage-backed securities in which the Company invests consist of agency residential pass-through certificates and CMOs. Agency residential pass-through certificates are securities representing interests in pools of mortgage loans secured by residential real property. Agency CMOs are securities that are structured instruments representing interests in agency residential pass-through certificates. Agency CMOs consist of multiple classes of securities.

Advisors’ Opinion:

  • [By Monica Gerson]

    American Capital Agency (NASDAQ: AGNC) shares fell 4.48% to $22.80 in the pre-market trading after the company reported Q3 comprehensive income of $0.45 per common share and net book value of $25.27 per common share.

  • [By Amanda Alix]

    Annaly has built its reputation on stellar yields produced by a savvy management team, building the business from its inception in 1997 to a company with a market capitalization of $15 billion and assets topping $133 billion. But there’s a relative newcomer that seems intent on knocking Annaly off of its throne: American Capital Agency (NASDAQ: AGNC  ) .

  • [By Dan Caplinger]

    CYS isn’t the best-known mortgage REIT in the industry, but it presents an interesting bargain right now. With shares of CYS trading well below its net asset value of $13.31, the REIT has a margin of safety that you won’t find with bigger rivals. Both Annaly Capital (NYSE: NLY  ) and American Capital Agency (NASDAQ: AGNC  ) trade at or above book value, compared to about a 7% discount at current prices for CYS.

  • [By Amanda Alix]

    Two Harbors is the third largest mortgage REIT, at a cap rate of $4.5 billion, and is the largest hybrid, investing in both government sponsored entity-backed securities, as well as non-agency. The two largest mREITs, Annaly Capital (NYSE: NLY  ) and American Capital Agency (NASDAQ: AGNC  ) buy only agency-backed paper.